Fresenius Medical Care (Frankfurt: FME) announced plans to execute a new share buyback program valued at approximately €1 billion over 12 months, according to a company statement.

The program will be implemented in tranches and is expected to begin shortly after the company completed its previous €1 billion share buyback program on April 30, 2026. The new initiative is authorized under approval granted by shareholders at the company's Annual General Meeting on May 21, 2026.

"The new share buyback program reflects our unwavering commitment to create value and return capital to shareholders," said Helen Giza, CEO and Chair of the Management Board. "Launching a new share buyback program shortly after successfully completing our initial €1 billion share buyback – ahead of schedule – demonstrates our financial strength and disciplined execution."

Chief Financial Officer Martin Fischer stated the program "is enabled by our strong operating cash-flow generation and financial discipline."

Fresenius Medical Care provides dialysis products and services to individuals with renal diseases. The company operates 3,539 dialysis clinics globally, treating approximately 290,000 patients. The company trades on the Frankfurt Stock Exchange under the ticker FME and on the New York Stock Exchange as FMS.

The share buyback program forms part of the company's capital allocation framework alongside dividend payments, according to the statement.